Journal of Infection and Public Health
Volume 2, Issue 3 , Pages 120-128 , 2009

Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections

  • Ayman M. Noreddin

      Affiliations

    • School of Pharmacy, Hampton University, Hampton, VA 23668, USA
    • ,
  • Walid F. Elkhatib

      Affiliations

    • Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota Duluth, 1110 Kirby Dr. Life Science 232, Duluth, MN 55812, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 218 726 6041; fax: +1 218 726 6500.

Received 20 May 2009 ,Revised 26 July 2009 ,Accepted 30 July 2009.

References 

  1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322
  2. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents. 1999;11:217–221
  3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135–138
  4. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001
  5. Chung P, McNamara PJ, Campion JJ, Evans ME. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2957–2965
  6. Madaras-Kelly KJ, Larsson AJ, Rotschafer JC. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 1996;37:703–710
  7. Bowker KE, Wootton M, Rogers CA, Lewis R, Holt HA, MacGowan AP. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J Antimicrob Chemother. 1999;44:661–667
  8. Schuck EL, Dalhoff A, Stass H, Derendorf H. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection. 2005;33(Suppl. 2):22–28
  9. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466–1477
  10. VanDevanter DR, Van Dalfsen JM. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatr Pulmonol. 2005;39:504–506
  11. Pierce GE. Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control. J Ind Microbiol Biotechnol. 2005;32:309–318
  12. Mikuniya T, Kato Y, Ida T. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother. 2007;13:285–290
  13. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother. 2008;62:1024–1026
  14. Opilla M. Epidemiology of bloodstream infection associated with parenteral nutrition. Am J Infect Control. 2008;36(S173):e5–e8
  15. Moser C, Van Gennip M, Bjarnsholt T. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host–pathogen interactions in cystic fibrosis. APMIS. 2009;117:95–107
  16. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol. 2001;183:6746–6751
  17. Heerden J, Turner M, Hoffmann D, Moolman J. Antimicrobial coating agents: can biofilm formation on a breast implant be prevented?. J Plast Reconstr Aesthetic Surg. 2009;62:610–617
  18. Kirstein MN, Brundage RC, Elmquist WF. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat. 2006;96:217–225
  19. Stoodley P, Lewandowski Z, Boyle JD, Lappin-Scott HM. Oscillation characteristics of biofilm streamers in turbulent flowing water as related to drag and pressure drop. Biotechnol Bioeng. 1998;57:536–544
  20. Duddu R, Chopp DL, Moran B. A two-dimensional continuum model of biofilm growth incorporating fluid flow and shear stress based detachment. Biotechnol Bioeng. 2008;
  21. Celmer D, Oleszkiewicz JA, Cicek N. Impact of shear force on the biofilm structure and performance of a membrane biofilm reactor for tertiary hydrogen-driven denitrification of municipal wastewater. Water Res. 2008;42:3057–3065
  22. Baillif S, Casoli E, Marion K. A novel in vitro model to study staphylococcal biofilm formation on intraocular lenses under hydrodynamic conditions. Invest Ophthalmol Vis Sci. 2006;47:3410–3416
  23. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193
  24. Joos B, Ledergerber B, Flepp M, Bettex JD, Luthy R, Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985;27:353–356
  25. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd edition. 1995;p. 18 [Section 1 part 3 Intravenous Dose]
  26. Allison DG, Gilbert P. Modification by surface association of antimicrobial susceptibility of bacterial populations. J Ind Microbiol. 1995;15:311–317
  27. Maira-Litran T, Allison DG, Gilbert P. An evaluation of the potential of the multiple antibiotic resistance operon (mar) and the multidrug efflux pump acrAB to moderate resistance towards ciprofloxacin in Escherichia coli biofilms. J Antimicrob Chemother. 2000;45:789–795
  28. Jumbe N, Louie A, Leary R. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112:275–285
  29. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931–936
  30. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis. 2005;40(Suppl. 2):S105–S114
  31. Huang V, Rybak MJ. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother. 2005;49:302–308
  32. Huang V, Rybak MJ. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. J Antimicrob Chemother. 2006;57:116–121
  33. LaPlante KL, Rybak MJ, Leuthner KD, Chin JN. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother. 2006;50:1298–1303
  34. Gander S, Hayward K, Finch R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother. 2002;49:301–308
  35. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother. 2005;56:337–343
  36. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2001;45:454–459
  37. Sakoulas G, Rose W, Rybak MJ. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008;46:220–224
  38. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2005;49:2735–2745
  39. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med. 1989;87:31S–36S
  40. Stewart PS. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother. 1996;40:2517–2522
  41. Stewart PS, Grab L, Diemer JA. Analysis of biocide transport limitation in an artificial biofilm system. J Appl Microbiol. 1998;85:495–500
  42. Giwercman B, Jensen ET, Hoiby N, Kharazmi A, Costerton JW. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother. 1991;35:1008–1010
  43. Bagge N, Schuster M, Hentzer M. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother. 2004;48:1175–1187
  44. Nakamura S, Higashiyama Y, Izumikawa K. The roles of the quorum-sensing system in the release of extracellular DNA, lipopolysaccharide, and membrane vesicles from Pseudomonas aeruginosa. Jpn J Infect Dis. 2008;61:375–378
  45. Shin DH, Choi YS, Cho YH. Unusual properties of catalase A (KatA) of Pseudomonas aeruginosa PA14 are associated with its biofilm peroxide resistance. J Bacteriol. 2008;190:2663–2670
  46. Jourdain B, Novara A, Joly-Guillou ML. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med. 1995;152:241–246
  47. Albert S, Kirchner J, Thomas H, Behne M, Schur J, Brade V. Role of quantitative cultures and microscopic examinations of endotracheal aspirates in the diagnosis of pulmonary infections in ventilated patients. J Hosp Infect. 1997;37:25–37

PII: S1876-0341(09)00055-0

doi: 10.1016/j.jiph.2009.07.004

Journal of Infection and Public Health
Volume 2, Issue 3 , Pages 120-128 , 2009

Article Tools

* Image Usage & Resolution